LONDON – The pioneers of gene therapy in Europe now aim to take the field to the next level, moving into the development of virally delivered antibodies in the treatment of central nervous system and muscular diseases, with Alzheimer’s disease one of the first targets.
LONDON – Alentis Therapeutics SA is now equipped to deliver initial proof of concept for its universal approach to treating fibrosis, after raising $67 million in an oversubscribed series B.
The hefty $107.5 million series B financing disclosed June 10 by Synthekine Inc. underscored Wall Street’s interest in engineered cytokines, where an army of companies is developing prospects at varying stages – including Bright Peak Therapeutics Inc., which pulled down a series B in almost exactly the same amount as Synthekine, and on the same day.
Biopharmas raising money in public or private financings, including: Ambrx, Cel-Sci, Century, Cyteir, Flagship, Hifibio, Inceptor, Isofol, Regencell, Synaptogenix, Verve.
PARIS – Affluent Medical SAS aims to raise $40 million on the Euronext Paris regulated market to finalize the development of three minimally invasive prostheses in urology and interventional cardiology. The Aix-en-Provence, France-based med-tech will issue 3,387,210 new shares. Affluent has already received subscription pledges exceeding $24 million, including $12 million from funds managed by Paris-based Truffle Capital.
TORONTO – Nanology Labs Inc. has raised C$3 million (US$2.49 million) in seed funding to advance development of a polymer-lipid platform that transports nanoparticles into human cells where they “reprogram” hypoxic or oxygen-deprived cancer tumors.
Genhouse Bio Co. Ltd. closed a series A financing round to raise more than ¥200 million (US$31 million) to support phase I studies of KRAS inhibitor GH-35 and SHP2 inhibitor GH-21 in China. The startup expects to enroll patients in trials testing the two compounds in the second half of this year, CEO Wang Kuifeng told BioWorld in an exclusive interview.
RSS
